# Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma

> **NCT01679860** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 92 (actual)

## Conditions studied

- Lymphoma, T-Cell, Peripheral

## Interventions

- **PROCEDURE:** Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT
- **DRUG:** Clin B (CHOP- CAMPATH) Chemo-immunotherapy

## Key facts

- **NCT ID:** NCT01679860
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-12
- **Final completion:** 2012-08
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2012-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679860, "Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01679860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*